326 related articles for article (PubMed ID: 23839909)
1. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus.
Carter LM; Isenberg DA; Ehrenstein MR
Arthritis Rheum; 2013 Oct; 65(10):2672-9. PubMed ID: 23839909
[TBL] [Abstract][Full Text] [Related]
2. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
3. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
4. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.
Cambridge G; Perry HC; Nogueira L; Serre G; Parsons HM; De La Torre I; Dickson MC; Leandro MJ; Edwards JC
J Autoimmun; 2014 May; 50():67-76. PubMed ID: 24365380
[TBL] [Abstract][Full Text] [Related]
5. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Ann Rheum Dis; 2007 Sep; 66(9):1259-62. PubMed ID: 17412738
[TBL] [Abstract][Full Text] [Related]
6. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
Ezeonyeji AN; Isenberg DA
Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015
[TBL] [Abstract][Full Text] [Related]
7. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
9. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
Cambridge G; Leandro MJ; Teodorescu M; Manson J; Rahman A; Isenberg DA; Edwards JC
Arthritis Rheum; 2006 Nov; 54(11):3612-22. PubMed ID: 17075806
[TBL] [Abstract][Full Text] [Related]
10. B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy.
de la Torre I; Moura RA; Leandro MJ; Edwards J; Cambridge G
Ann Rheum Dis; 2010 Dec; 69(12):2181-8. PubMed ID: 20581016
[TBL] [Abstract][Full Text] [Related]
11. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
12. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
[TBL] [Abstract][Full Text] [Related]
13. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
Vincent FB; Northcott M; Hoi A; Mackay F; Morand EF
Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation.
Turner-Stokes T; Lu TY; Ehrenstein MR; Giles I; Rahman A; Isenberg DA
Rheumatology (Oxford); 2011 Aug; 50(8):1401-8. PubMed ID: 21398661
[TBL] [Abstract][Full Text] [Related]
16. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
17. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab.
Hoyer BF; Mumtaz IM; Loddenkemper K; Bruns A; Sengler C; Hermann KG; Maza S; Keitzer R; Burmester GR; Buttgereit F; Radbruch A; Hiepe F
Ann Rheum Dis; 2012 Jan; 71(1):75-9. PubMed ID: 21953334
[TBL] [Abstract][Full Text] [Related]
18. Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus.
Friebus-Kardash J; Branco L; Ribi C; Chizzolini C; Huynh-Do U; Dubler D; Roux-Lombard P; Dolff S; Kribben A; Eisenberger U; Trendelenburg M
Nephrol Dial Transplant; 2018 Jan; 33(1):54-64. PubMed ID: 28992184
[TBL] [Abstract][Full Text] [Related]
19. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time.
Becker-Merok A; Nikolaisen C; Nossent HC
Lupus; 2006; 15(9):570-6. PubMed ID: 17080911
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab.
Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y
J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
